Related Experiment Videos
Pro-T ALL: immunophenotypical analyses
M C Béné1, ,
1Laboratoire d'Immunologie du CHU, Faculté de Médecine de Nancy, Vandoeuvre les Nancy, France. bene@medecine.uhp-nancy.fr
Journal of Biological Regulators and Homeostatic Agents
|March 25, 2005
Summary
Pro-T acute lymphoblastic leukemia (T-ALL) is a rare bone marrow disease characterized by immature T-cells. This review examines the limited literature and proposed mechanisms for T-ALL development.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Pro-T acute lymphoblastic leukemia (T-ALL), also known as T-I ALL, is an exceptionally rare hematologic malignancy.
- This leukemia is defined by the proliferation of T-cell precursors lacking most T-lineage markers except for intracytoplasmic CD3 and surface CD7.
- T-ALL cases may exhibit markers of immaturity and myeloid lineage without meeting criteria for biphenotypic acute leukemia (BAL).
Purpose of the Study:
- To review the existing literature on Pro-T acute lymphoblastic leukemia.
- To consolidate current understanding of the pathobiology and diagnostic features of T-ALL.
- To explore proposed mechanisms underlying T-ALL development.
Main Methods:
- A comprehensive literature search was conducted using the Medline database.
- Publications specifically addressing T-I ALL were identified and reviewed.
- Information regarding T-ALL pathogenesis, primarily from animal studies, was analyzed.
Main Results:
- The literature on T-I ALL is sparse, highlighting its rarity.
- Key immunophenotypic markers (intracellular CD3, surface CD7) define T-ALL.
- The study discusses potential mechanisms contributing to T-ALL, drawing from experimental models.
Conclusions:
- T-I ALL represents a distinct and poorly understood subtype of acute lymphoblastic leukemia.
- Further research is needed to elucidate the specific molecular events driving T-ALL.
- Understanding T-ALL pathogenesis may offer insights into early T-cell development and leukemia initiation.